Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | EVP & Chief Financial Officer | February 10, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,282 |
Ending reported balance
After 2026-02-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-10 · Grant · Acquired 26,421 · Balance 153,088 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Row 2 · 2026-02-10 · Grant · Acquired 32,734 · Balance 185,822 F2: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Row 3 · 2026-02-10 · Tax withholding · Disposed 11,861 · Balance 173,961 F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Row 4 · 2026-02-10 · Tax withholding · Disposed 26,679 · Balance 147,282 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 12, 2026 16:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 26,679 | $46.75 | $1,247,243.25 |
DisclosureSEC source: 0001862082-26-000002 · form4-02122026_040203.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,282 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 11,861 | $46.75 | $554,501.75 |
DisclosureSEC source: 0001862082-26-000002 · form4-02122026_040203.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,961 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 32,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001862082-26-000002 · form4-02122026_040203.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,822 F2 · shares: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 26,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001862082-26-000002 · form4-02122026_040203.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,088 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 16:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,858 | $41.28 | $200,516.86 |
DisclosureSEC source: 0001862082-25-000004 · form4-11072025_091106.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.00 to $41.75, inclusive. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 16:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,142 | $40.38 | $1,015,236.47 |
DisclosureSEC source: 0001862082-25-000004 · form4-11072025_091106.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 17:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,396 | $30.03 | $192,068.68 |
DisclosureSEC source: 0001062993-25-006149 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.50, inclusive. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,206 | $30.00 | $36,181.33 |
DisclosureSEC source: 0001062993-25-006149 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 17:35 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 977 | $30.00 | $29,313.32 |
DisclosureSEC source: 0001062993-25-005753 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 16:49 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 10,445 | $30.01 | $313,412.67 |
DisclosureSEC source: 0001062993-25-005395 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,246 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 16:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,504 | $30.00 | $45,121.05 |
DisclosureSEC source: 0001062993-25-005021 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,691 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 16:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,949 | $30.00 | $58,470.00 |
DisclosureSEC source: 0001062993-25-005021 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,195 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 22,317 | $30.52 | $681,114.84 |
DisclosureSEC source: 0001062993-25-002178 · form4.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,144 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 8,109 | $30.52 | $247,486.68 |
DisclosureSEC source: 0001062993-25-002178 · form4.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,461 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 26,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002178 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,570 F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 26,957 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 51,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002178 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,613 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 19,710 | $34.21 | $674,367.80 |
DisclosureSEC source: 0001062993-24-011413 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.94 to $34.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 9,453 | $33.70 | $318,566.10 |
DisclosureSEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,555 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 16,868 | $33.70 | $568,451.60 |
DisclosureSEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,008 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 30,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,876 F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,856 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 40,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003170 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,020 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 31,640 | $23.77 | $752,165.06 |
DisclosureSEC source: 0001062993-23-007174 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,420 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.47 to $24.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 3,887 | $26.75 | $103,977.25 |
DisclosureSEC source: 0001062993-23-003477 · form4.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,060 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 6,967 | $26.75 | $186,367.25 |
DisclosureSEC source: 0001062993-23-003477 · form4.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,947 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 12,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-003477 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,914 F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 12,565 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-003477 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,349 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,350 | $17.35 | $75,472.50 |
DisclosureSEC source: 0001062993-22-020614 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.25 to $17.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,237 | $17.63 | $21,808.31 |
DisclosureSEC source: 0001062993-22-004322 · form4.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,654 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,821 | $17.63 | $49,734.23 |
DisclosureSEC source: 0001062993-22-004322 · form4.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,891 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-004322 · form4.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,712 F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,212 performance share units granted in the issuer's prior fiscal year. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004322 · form4.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| February 10, 2022 Filed Mar 3, 2022 16:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,237 | $17.63 | $21,808.31 |
DisclosureSEC source: 0001062993-22-006643 · form4a.xml · nonDerivative · entry 4 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,654 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2022 Filed Mar 3, 2022 16:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,821 | $17.63 | $49,734.23 |
DisclosureSEC source: 0001062993-22-006643 · form4a.xml · nonDerivative · entry 3 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,891 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Mar 3, 2022 16:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-006643 · form4a.xml · nonDerivative · entry 2 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,712 F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,212 performance share units granted in the issuer's prior fiscal year. Read SEC document |
| February 10, 2022 Filed Mar 3, 2022 16:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006643 · form4a.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| May 24, 2021 Filed May 24, 2021 17:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000452 · edgar.xml · nonDerivative · entry 1 Tupper Colleen · CIK 0001862082 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments (in each case, rounded up to the nearest whole share of common stock) over the following three year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.